| MeSH term | MeSH ID | Detail |
|---|---|---|
| Denys-Drash Syndrome | D030321 | 1 associated lipids |
| Hypophosphatemia | D017674 | 1 associated lipids |
| Moyamoya Disease | D009072 | 1 associated lipids |
| Latent Tuberculosis | D055985 | 1 associated lipids |
| Leukoplakia | D007971 | 1 associated lipids |
| Oculomotor Nerve Diseases | D015840 | 1 associated lipids |
| Scorpion Stings | D065008 | 1 associated lipids |
| Esophageal Perforation | D004939 | 1 associated lipids |
| Mediastinitis | D008480 | 2 associated lipids |
| Coproporphyria, Hereditary | D046349 | 1 associated lipids |
| Ileus | D045823 | 3 associated lipids |
| Rectal Diseases | D012002 | 1 associated lipids |
| Angiolymphoid Hyperplasia with Eosinophilia | D000796 | 1 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Sugden PH | Signalling pathways in cardiac myocyte hypertrophy. | 2001 | Ann. Med. | pmid:11817656 |
| Sun L et al. | Cellular and molecular consequences of calcineurin A alpha gene deletion. | 2007 | Ann. N. Y. Acad. Sci. | pmid:17872390 |
| Shipston MJ et al. | Glucocorticoid negative feedback in pituitary corticotropes. Pivotal role for calcineurin inhibition of adenylyl cyclase. | 1994 | Ann. N. Y. Acad. Sci. | pmid:7529975 |
| Iwanaga Y et al. | Living donor islet transplantation, the alternative approach to overcome the obstacles limiting transplant. | 2006 | Ann. N. Y. Acad. Sci. | pmid:17130575 |
| Xu L et al. | Potential for pharmacology of ryanodine receptor/calcium release channels. | 1998 | Ann. N. Y. Acad. Sci. | pmid:10603942 |
| Bers DM et al. | Factors that control sarcoplasmic reticulum calcium release in intact ventricular myocytes. | 1998 | Ann. N. Y. Acad. Sci. | pmid:10603944 |
| Engelbrecht ME et al. | The effect of immunosuppressants on human leukocyte NADPH oxidase. | 1994 | Ann. N. Y. Acad. Sci. | pmid:7518204 |
| Zuany-Amorim C et al. | Modulation by rm interferon-gamma and CD4+ T-lymphocytes of allergic eosinophil accumulation in the mice peritoneal cavity. | 1994 | Ann. N. Y. Acad. Sci. | pmid:7518212 |
| Nagai H et al. | The role of interleukin-5 (IL-5) in allergic airway hyperresponsiveness in mice. | 1996 | Ann. N. Y. Acad. Sci. | pmid:8906215 |
| Clipstone NA and Crabtree GR | Calcineurin is a key signaling enzyme in T lymphocyte activation and the target of the immunosuppressive drugs cyclosporin A and FK506. | 1993 | Ann. N. Y. Acad. Sci. | pmid:7509131 |
| Takahara S | Efficacy of FK506 in renal transplantation. | 1993 | Ann. N. Y. Acad. Sci. | pmid:7509132 |
| Thomson AW et al. | Incidence of CD4+ IL-2R alpha+ and CD4+ CD45RA+ T-cells in progressive multiple sclerosis and the influence of short-term (3 months) FK 506 therapy. | 1993 | Ann. N. Y. Acad. Sci. | pmid:7509133 |
| Lemster B et al. | FK 506 inhibits cytokine gene and adhesion molecule expression in psoriatic skin lesions. | 1993 | Ann. N. Y. Acad. Sci. | pmid:7509134 |
| Tamura K et al. | Inhibitory effect of FK 506 on autoimmune thyroid disease in the PVG rat. | 1993 | Ann. N. Y. Acad. Sci. | pmid:7509135 |
| Ochiai T et al. | Combination of immunosuppressive drugs for organ transplantation. | 1993 | Ann. N. Y. Acad. Sci. | pmid:7509136 |
| Wiederrecht G et al. | The mechanism of action of FK-506 and cyclosporin A. | 1993 | Ann. N. Y. Acad. Sci. | pmid:7509138 |
| Lee RK and Wurtman RJ | Regulation of APP synthesis and secretion by neuroimmunophilin ligands and cyclooxygenase inhibitors. | 2000 | Ann. N. Y. Acad. Sci. | pmid:11193162 |
| Christensen BG | FK-506: its role in immunosuppression. | 1993 | Ann. N. Y. Acad. Sci. | pmid:7689803 |
| Kino T and Goto T | Discovery of FK-506 and update. | 1993 | Ann. N. Y. Acad. Sci. | pmid:7689804 |
| Parsons WH et al. | FK-506--a novel immunosuppressant. | 1993 | Ann. N. Y. Acad. Sci. | pmid:7689805 |
| Zenke G et al. | Molecular mechanisms of immunosuppression by cyclosporins. | 1993 | Ann. N. Y. Acad. Sci. | pmid:7689806 |
| Clardy J | Structural studies of complexed FK-506 binding protein. | 1993 | Ann. N. Y. Acad. Sci. | pmid:7689808 |
| Starzl TE et al. | Allograft and xenograft acceptance under FK-506 and other immunosuppressant treatment. | 1993 | Ann. N. Y. Acad. Sci. | pmid:7689809 |
| Reem GH et al. | FK-506 inhibits the IL-2-independent induction of the activation antigen CD 69. | 1993 | Ann. N. Y. Acad. Sci. | pmid:7689811 |
| Mollison KW et al. | Comparison of FK-506, rapamycin, ascomycin, and cyclosporine in mouse models of host-versus-graft disease and heterotopic heart transplantation. | 1993 | Ann. N. Y. Acad. Sci. | pmid:7689812 |
| Ponseti JM et al. | Tacrolimus for myasthenia gravis: a clinical study of 212 patients. | 2008 | Ann. N. Y. Acad. Sci. | pmid:18096852 |
| Paterson DL et al. | Could a herpesvirus mimic tacrolimus-induced leukoencephalopathy? | 1997 | Ann. Neurol. | pmid:9266742 |
| Caprariello AV et al. | Apoptosis of oligodendrocytes in the central nervous system results in rapid focal demyelination. | 2012 | Ann. Neurol. | pmid:23034912 |
| Keswani SC et al. | FK506 is neuroprotective in a model of antiretroviral toxic neuropathy. | 2003 | Ann. Neurol. | pmid:12509848 |
| Dawson TM | Immunosuppressants, immunophilins, and the nervous system. | 1996 | Ann. Neurol. | pmid:8871573 |
| Small SL et al. | Immunosuppression-induced leukoencephalopathy from tacrolimus (FK506) | 1996 | Ann. Neurol. | pmid:8871576 |
| Roberts WK et al. | A destructive feedback loop mediated by CXCL10 in central nervous system inflammatory disease. | 2015 | Ann. Neurol. | pmid:26224283 |
| Wijdicks EF et al. | FK506-induced neurotoxicity in liver transplantation. | 1994 | Ann. Neurol. | pmid:7512320 |
| Nelson M et al. | Direct revascularization is superior for rat parathyroid allotransplantation with FK506. | 2005 | Ann. Otol. Rhinol. Laryngol. | pmid:15825570 |
| Gerster JC et al. | Gout in liver transplant patients receiving tacrolimus. | 2004 | Ann. Rheum. Dis. | pmid:15194597 |
| Igarashi T et al. | Central nervous system toxicity related to FK506 in patients with Behçet's disease. | 1994 | Ann. Rheum. Dis. | pmid:7517134 |
| Villaverde V et al. | Leg bone pain syndrome in a kidney transplant patient treated with tacrolimus (FK506) | 1999 | Ann. Rheum. Dis. | pmid:10577370 |
| Duddridge M and Powell RJ | Treatment of severe and difficult cases of systemic lupus erythematosus with tacrolimus. A report of three cases. | 1997 | Ann. Rheum. Dis. | pmid:9462174 |
| Lightman S et al. | Pegylated interferon-α-2b reduces corticosteroid requirement in patients with Behçet's disease with upregulation of circulating regulatory T cells and reduction of Th17. | 2015 | Ann. Rheum. Dis. | pmid:25269831 |
| Lampropoulos CE and D' Cruz DP | Topical tacrolimus treatment in a patient with dermatomyositis. | 2005 | Ann. Rheum. Dis. | pmid:16100347 |
| Mok CC et al. | Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up. | 2016 | Ann. Rheum. Dis. | pmid:25550339 |
| Schlegel A et al. | Hypothermic Oxygenated Perfusion (HOPE) downregulates the immune response in a rat model of liver transplantation. | 2014 | Ann. Surg. | pmid:25243553 |
| Fealy MJ et al. | Efficacy of rapamycin and FK 506 in prolonging rat hind limb allograft survival. | 1994 | Ann. Surg. | pmid:7507657 |
| Vivarelli M et al. | Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence. | 2008 | Ann. Surg. | pmid:18948815 |
| Petruzzo P et al. | Outcomes after bilateral hand allotransplantation: a risk/benefit ratio analysis. | 2015 | Ann. Surg. | pmid:24646555 |
| Todo S et al. | Single-center experience with primary orthotopic liver transplantation with FK 506 immunosuppression. | 1994 | Ann. Surg. | pmid:7522431 |
| Jain A et al. | What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients. | 1999 | Ann. Surg. | pmid:10493490 |
| Lerut J et al. | Tacrolimus monotherapy in liver transplantation: one-year results of a prospective, randomized, double-blind, placebo-controlled study. | 2008 | Ann. Surg. | pmid:19092340 |
| Bartlett ST et al. | Equivalent success of simultaneous pancreas kidney and solitary pancreas transplantation. A prospective trial of tacrolimus immunosuppression with percutaneous biopsy. | 1996 | Ann. Surg. | pmid:8857849 |
| Todo S et al. | Intestinal transplantation in composite visceral grafts or alone. | 1992 | Ann. Surg. | pmid:1384443 |